1720nm-1800nm tunable chirped pulse amplification based on thulium-doped fiber

Chirped pulse amplification (CPA) has been adopted as a commonly used methodology to obtain powerful ultrashort laser pulses since its first demonstration. However, wavelength-tunable CPA systems are rarely reported. Wavelength-tunable ultrashort and intense laser pulses are desired in various fields like nonlinear spectroscopy and optical parametric amplification. In this work, we report a 1720 nm -1800 nm tunable CPA system based on a single-mode Tm-doped fiber covering the middle wavelength band of the third biological window. The tunable CPA system delivers ultrashort pulses varied between ~300 to 500 fs depending on the central wavelength emission at the fixed repetition rate of 22.7 MHz. The maximum average power ranges from 126 mW at 1720 nm to 294 mW at 1800 nm following the gain shape of Tm-doped fiber. Considering the specific wave-length range, this tunable CPA system is highly desired for biomedical imaging, sensing and parametric amplifiers for mid-infrared light generation

Prognostic Value of FGFR Gene Amplification in Patients with Different Types of Cancer: A Systematic Review and Meta-Analysis

<div><p>Background</p><p>Fibroblast growth factor receptor (FGFR) gene amplification has been reported in different types of cancer. We performed an up-to-date meta-analysis to further characterize the prognostic value of FGFR gene amplification in patients with cancer.</p><p>Methods</p><p>A search of several databases, including MEDLINE (PubMed), EMBASE, Web of Science, and China National Knowledge Infrastructure, was conducted to identify studies examining the association between FGFR gene amplification and cancer. A total of 24 studies met the inclusion criteria, and overall incidence rates, hazard risk (HR), overall survival, disease-free survival, and 95% confidence intervals (CIs) were calculated employing fixed- or random-effects models depending on the heterogeneity of the included studies.</p><p>Results</p><p>In the meta-analysis of 24 studies, the prevalence of FGFR gene amplification was <i>FGFR1</i>: 0.11 (95% CI: 0.08–0.13) and <i>FGFR2</i>: 0.04 (95% CI: 0.02–0.06). Overall survival was significantly worse among patients with FGFR gene amplification: <i>FGFR1</i> [HR 1.57 (95% CI: 1.23–1.99); <i>p</i> = 0.0002] and <i>FGFR2</i> [HR 2.27 (95% CI: 1.73–3.00); <i>p</i><0.00001].</p><p>Conclusions</p><p>Current evidence supports the conclusion that the outcomes of patients with FGFR gene amplified cancers is worse than for those with non-FGFR gene amplified cancers.</p></div

Flow diagram of the study selection process.

<p>Flow diagram of the study selection process.</p

Molecular Engineering of Aqueous Soluble Triarylboron-Compound-Based Two-Photon Fluorescent Probe for Mitochondria H₂S with Analyte-Induced Finite Aggregation and Excellent Membrane Permeability

Hydrogen sulfide (H₂S) is a multifunctional signaling molecule that participates in many important biological processes. Herein, by functionalizing triarylboron with cyclen and diphenylamine, we synthesized TAB-1, TAB-2, and TAB-3 for H₂S recongnization by rational design of molecular structures. Among them, aqueous soluble TAB-2 possesses excellent properties, including large two-photon action cross section, membrane permeability and can effectively complex with Cu²⁺. The complex of TAB-2-Cu²⁺ can selectively detect H₂S with an instant response and mitochondria targeted. Moreover, the H₂S-induced finite aggregation of indicators enhances their photostability and causes variation of the fluorescence lifetime. TAB-2-Cu²⁺ has also been successfully applied for the mitochondria H₂S imaging in NIH/3T3 fibroblast cells by TPM and FLIM

Forest plots describing the prevalence of <i>FGFR</i> amplification.

<p>(A) Analysis of the prevalence of <i>FGFR1</i> amplification. (B) Analysis of the prevalence of <i>FGFR2</i> amplification. The horizontal lines represent 95% CIs for estimating prevalence of FGFR gene amplification.(▪) Overall estimates of the effects.CI, confidence interval; ES, estimation.</p

Funnel plots of the association between <i>FGFR</i> amplification and overall survival.

<p>(A) Publication bias for <i>FGFR1</i> amplification and overall survival in various cancers. (B) Publication bias for <i>FGFR2</i> amplification and overall survival in gastric cancer. Each point represents a separate study. Log [Hazard Ratio], natural logarithm of HR; SE, standard error.</p

Forest plots of studies evaluating HR of overall survival, comparing high <i>FGFR</i> amplification and non-amplification.

<p>(A) Analysis of <i>FGFR1</i> amplification and overall survival in various cancers. (B) Analysis of <i>FGFR2</i> amplification and overall survival in gastric cancer. The horizontal lines represent 95% CIs for estimating HR of FGFR gene amplification versus non-amplification. (▪) Overall estimates of the effects. CI, confidence interval; HR, hazard ratio; IV, XXX; SE, standard error.</p

Additional file 1: Figure S1. of Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study

Manifestation of hypertension, proteinuria, hand and foot syndrome during apatinib treatment. HTN: hypertension; PrU: proteinuria; HFS: hand and foot syndrome. (TIF 1373 kb